When Will Novavax Vaccines Be FDA Authorized As Covid-19 Boosters?

But it’s been eight weeks since Novavax announced that they had submitted a emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA). This was an application for their protein-based Covid-19 vaccine Nuvaxovid (NVX-CoV2373) to be used as a booster, meaning a follow-up vaccine dose after someone has already received the primary series of Covid-19 shots. And some on social media have questioned why it’s taking so long for the FDA to consider the EUA amendment application to be A-OK.